Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip. - Conway J; Delanois RE; Mont MA; Stavrakis A; McPherson E; Stolarski E; Incavo S; Oakes D; Salvagno R; Adams JS; Kisch-Hancock A; Tenorio E; et al. (Antimicrobial agents and chemotherapy, 2024)